Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy

Pediatric Endocrinology Reviews

Volumn 2, Issue SUPPL. 2, 2004, Pages 279-281

  Platis, Odysseas ^a,d   Anagnostopoulos, Georgios ^a   Farmaki, Kallisteni ^a   Posantzis, Markos ^a   Gotsis, Efstathios ^b   Tolis, Georgios ^c  

^a IASO GENERAL HOSPITAL   (Greece)

^b Encepllalos/Euromedica Institute   (Greece)

^c HIPPOKRATION HOSPITAL   (Greece)

^d General Hospital of Corinth   (Greece)

Author keywords

Chelation therapy; Diabetes mellitus; Haemochromatosis; Impaired glucose tolerance; Thalassaemia major

Indexed keywords

DEFERIPRONE; DEFEROXAMINE MESYLATE; FERRITIN; GLUCOSE; IRON;

ADULT; CHELATION THERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE METABOLISM; HEMOCHROMATOSIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; IRON OVERLOAD; MALE; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; THALASSEMIA MAJOR; TREATMENT OUTCOME;

ADULT; BETA-THALASSEMIA; CHELATION THERAPY; DEFEROXAMINE; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MALE; PYRIDONES;

EID: 12544253460     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Saudek CD, Hemm RM, Peterson CM. Abnormal glucose tolerance in beta-thalassemia major. Metabolism 1977;26(1):43-52
2. Merkel PA, Simonson DC, Amiel SA, Plewe G, Sherwin RS, Pearson HA, Tamborlane WV. Insulin resistance and hyperinsulinemia in patients with thalassaemia major treated by hypertransfusion. N Engl J Med 1988;318:809-814
3. Wonke B, Hanslip JI. Glucose intolerance and diabetes in thalassaemia major. In: Ando S, Brancati C, eds. Endocrine disorders in thalassaemia. Berlin-Heidelberg: Springer-Verlag 1995;65-67
4. Karagiorga-Lagana M, Chatziliami A, Katsantoni A, Karabatsos F, Fragodimitri C, Tapaki G, Jousef J, Giannaki M, Al-Quadreh A. Secondary diabetes mellitus in thalassaemic patients. In: Ando S, Brancati C, eds. Endocrine disorders in thalassaemia. Berlin-Heidelberg: Springer-Verlag 1995;69-72
5. Italian Working Group on Endocrine Complications in Non-endocrine Diseases. Multicentre study on prevalence of endocrine complications in thalassaemia major. Clin Endocrinol 1995;42:581-586
6. Anonymous. Endocrine abnormalities in thalassaemic patients. TIF Magazine 2001;32:12
7. Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B. Factors determining glucose tolerance in patients with thlalassemia major. J Clin Endocrinol Metab 1993;77:478-483
8. Cavallo-Perin P, Pacini G, Cerutti F, Bessone A, Condo C, Sacchetti I, Piga A, Pagano A, Pagano G. Insulin resistance and hyperinsulinemia in homozygous beta-thalassemia. Metabolism 1995;44:281-286
9. Pappas S, Donohue SM, Denver AE, Mohamed-Ali Y, Goubet S, Yudkin JS. Glucose intolerance in thalassemia major is related to insulin resistance and hepatic dysfunction. Metabolism 1996;45:652-657
10. Haffner SM, Gonzales C, Miettinen H, Kennedy E, Stern MP. A prospective analysis of the HOMA model. Diabetes Care 1996;19:1138-1141
11. Link G, Konijn AM, Breuer W, et al. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labelled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001;138:130-138
12. Grady RW, Berdoukas VA, Rachmilewitz A, et al. Combinations of desferrioxamine and deferiprone markedly enhance iron excretion. 44th Annual Meeting of the American Society of Hematology; 2002 Dec 6-10; Philadelphia, United States, p. 241a